Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-004098-23
    Sponsor's Protocol Code Number:Tide-A
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-06-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-004098-23
    A.3Full title of the trial
    Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
    Studio di fase II sull’uso in prima linea di avelumab in combinazione con axitinib intermittente in pazienti con carcinoma renale metastatico (studio Tide-A)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
    Studio di fase II sull’uso in prima linea di avelumab in combinazione con axitinib intermittente in pazienti con carcinoma renale metastatico (studio Tide-A)
    A.3.2Name or abbreviated title of the trial where available
    Tide-A
    Tide-A
    A.4.1Sponsor's protocol code numberTide-A
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCONSORZIO ONCOTECH
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationFondazione Policlinico Universitario Agostino Gemelli IRCCS
    B.5.2Functional name of contact pointArea Gastroenterologia e Oncologia
    B.5.3 Address:
    B.5.3.1Street AddressLargo F. Vito 1
    B.5.3.2Town/ cityRoma
    B.5.3.3Post code00168
    B.5.3.4CountryItaly
    B.5.6E-mailroberto.iacovelli@policlinicogemelli.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name INLYTA - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderPFIZER LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameInlyta
    D.3.2Product code [Axitinib]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeAxitinib
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name INLYTA - 3 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALLUMINIO/ALLUMINIO) 56 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderPFIZER LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameInlyta
    D.3.2Product code [Axitinib]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeaxitinib
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name INLYTA - 5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderPFIZER LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameInlyta
    D.3.2Product code [axitinib]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeAxitinib
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAvelumab
    D.3.2Product code [Avelumab]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeAvelumab
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number800
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    metastatic renal cell carcinoma
    Carcinoma renale metastatico
    E.1.1.1Medical condition in easily understood language
    metastatic renal cell carcinoma
    Carcinoma renale metastatico
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10050513
    E.1.2Term Metastatic renal cell carcinoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10050513
    E.1.2Term Metastatic renal cell carcinoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the activity of the axitinib discontinuation in patients who received a previous induction with axitinib and avelumab.
    Valutare l'attività della sospensione di axitinib nei pazienti che hanno ricevuto una precedente induzione con axitinib e avelumab
    E.2.2Secondary objectives of the trial
    • To evaluate the efficacy of the combination in terms of the control of the disease
    • To evaluate the efficacy of the combination in terms of the overall survival.
    • To evaluate the safety of the combination and of the discontinuation.
    • To evaluate the quality of life in patients who receive the combination and discontinue the tyrosine kinase inhibitor
    • Valutare l'efficacia della combinazione dei due farmaci in termini di controllo della malattia;
    • Valutare l'efficacia della combinazione dei due farmaci in termini di sopravvivenza globale;
    • Valutare la sicurezza della combinazione dei due farmaci e della successiva sospensione del TKI;
    • Valutare la qualità della vita dei pazienti che ricevono la combinazione dei due farmaci e successivamente la sospensione del TKI.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Each patient must meet the following criteria to be enrolled in this study.
    1. Histologically or cytologically confirmed advanced RCC with predominantly clear-cell subtype with primary tumor resected.
    2. Availability of tumor tissue sample for biomarker analysis.
    3. Male or female subjects aged = 18 years
    4. At least one measurable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
    5. Eastern Cooperative Oncology Group performance status 0 or 1.
    6. Adequate organ and bone marrow function based upon meeting all of the following laboratory criteria within 10 days before the start of treatment:
    I. Absolute neutrophil count (ANC) = 1500/mm3 (= 1.5 GI/L).
    II. Platelets = 100,000/mm3 (= 100 GI/L).
    III. Hemoglobin = 9 g/dL (= 90 g/L).
    IV. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 × upper limit of normal.
    V. Total bilirubin = 1.5 × the upper limit of normal. For subjects with Gilbert’s disease = 3 mg/dL (= 51.3 µmol/L).
    VI. Serum creatinine = 2.0 × upper limit of normal or calculated creatinine clearance = 30 mL/min (= 0.5 mL/sec) using the Cockroft-Gault.
    7. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
    8. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for at least 30 days after the last dose of study treatment. Acceptable methods are provided in Appendix E.
    9. Negative serum or urine pregnancy test at screening for women of childbearing potential.
    Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons. A lactating woman should be advised to not to breastfeed during treatment and for at least one month after the last dose of avelumab.
    Ciascun paziente deve soddisfare i seguenti criteri di inclusione per poter essere arruolato in questo studio:
    1. RCC avanzato, confermato istologicamente o citologicamente, con sottotipo prevalentemente di cellule chiare con resezione del tumore primario;
    2. Disponibilità di tessuto tumorale per l’analisi dei biomarcatori;
    3. Pazienti di sesso maschile o femminile di età = 18 anni;
    4. Almeno una lesione misurabile, come definita dai Criteri di Valutazione della Risposta nei Tumori Solidi (RECIST) versione 1.1;
    5. ECOG Performance Status di 0 o 1;
    6. Funzione d’organo e del midollo osseo adeguate, basate sul rispetto di tutti i seguenti criteri di laboratorio valutati entro 10 giorni dall'inizio del trattamento:
    I. Conta assoluta dei neutrofili (ANC) = 1500 / mm3 (= 1,5 GI / L).
    II. Piastrine = 100.000/mm3 (= 100 GI/L).
    III. Emoglobina = 9 g/dL (= 90 g/L).
    IV. Alanina aminotransferasi (ALT) e aspartato aminotransferasi (AST) <2,5 volte il limite normale superiore.
    V. Bilirubina totale = 1,5 volte il limite normale superiore. Per soggetti con malattia di Gilbert = 3 mg dL (= 51,3 µmol/L).
    VI. Creatinina sierica = 2,0 volte il limite normale superiore oppure clearance della creatinina calcolata = 30 mL / min (= 0,5 mL / sec) utilizzando la formula di Cockroft-Gault.
    7. Capacità di comprendere e rispettare i requisiti del protocollo e di firmare il modulo di consenso informato.
    8. I soggetti fertili, sessualmente attivi, e i loro partner devono concordare di utilizzare metodi contraccettivi accettati dal punto di vista medico (ad es. metodi di barriera, tra cui preservativo maschile, preservativo femminile o diaframma con gel spermicida) nel corso dello studio e per almeno 30 giorni dopo l'ultima dose del trattamento in studio.
    9. Test di gravidanza su siero o urine negativo allo screening per donne in età fertile.
    Le donne in età fertile non devono essere in stato di gravidanza allo screening. Le femmine in età fertile sono definite come femmine in premenopausa in grado di rimanere incinta (cioè, femmine che hanno avuto evidenza di mestruazioni negli ultimi 12 mesi, ad eccezione di quelle che avevano subito precedentemente un'isterectomia). Tuttavia, le donne amenorroiche per 12 o più mesi sono ancora considerate potenzialmente fertili se l'amenorrea è possibilmente dovuta a chemioterapia, antiestrogeni, basso peso corporeo, soppressione ovarica o altri motivi. Una donna che allatta non potrà allattare durante il trattamento e per almeno un mese dopo l'ultima dose di avelumab
    E.4Principal exclusion criteria
    1. Prior treatment with systemic therapy for advanced RCC
    2. Prior adjuvant or neoadjuvant therapy
    3. Bulky or symptomatic disease or hepatic metastases.
    4. Prior treatment with any agent specifically targeting T-cell co-stimulation or checkpoint pathways
    5. Active seizure disorder or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis
    6. Diagnosis of any non-RCC malignancy occurring within 2 years prior to the date of the start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix or low-grade prostate cancer (=pT2,N0; Gleason 6) with no plans for treatment intervention.
    7. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the start of treatment. Systemic treatment with radionuclides within 6 weeks before the start of treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
    8. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months before the start of treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of treatment.
    9. Concomitant anticoagulation at therapeutic doses with oral anticoagulants
    10. In past 6 months: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack.
    11. Chronic treatment with corticosteroids or other immunosuppressive agents . Subjects with brain metastases requiring systemic corticosteroid are not eligible.
    12. The subject has uncontrolled, significant intercurrent or recent illness
    13. Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before the start of treatment. Complete wound healing from major surgery must have occurred 1 month before the start of treatment and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before the start of treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
    14. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 msec within 1 month before the start of treatment
    15. Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
    16. Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
    17. Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
    18. History of substance abuse or medical, psychological, or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.
    19. Illness or medical conditions that are unstable or could jeopardize the safety of the patient and his or her compliance in the study.
    20. Pregnant or lactating females.
    21. Inability to swallow tablets or capsules.
    22. Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE Grade = 3).
    1. Trattamento sistemico precedente per RCC avanzato.
    2. Terapia adiuvante o neoadiuvante precedente.
    3. Malattia bulky o sintomatica o che presenta metastasi epatiche.
    4. Precedente terapia con qualsiasi agente mirato specificamente alla co-stimolazione delle cellule T o ai checkpoint pathways.
    5. Disturbo convulsivo attivo o evidenza di metastasi cerebrali, compressione del midollo spinale o meningite carcinomatosa.
    6. Diagnosi di qualsiasi tumore diverso da RCC avvenuta entro 2 anni dalla data di inizio del trattamento, ad eccezione del carcinoma cutaneo a cellule basali o squamose adeguatamente trattato o carcinoma in situ della mammella o della cervice o cancro alla prostata di basso grado (=pT2, N0; Gleason 6), per il quale non sono previsti trattamenti.
    7. Radioterapia per metastasi ossee entro 2 settimane dalla data di inizio del trattamento; qualsiasi altra radioterapia esterna entro 4 settimane dall'inizio del trattamento. Trattamento sistemico con radionuclidi entro 6 settimane dall'inizio del trattamento. I soggetti con complicanze in corso clinicamente rilevanti dalla precedente radioterapia non sono elegibili.
    8. Metastasi cerebrali note o malattia epidurale cranica a meno che non siano state adeguatamente trattate con radioterapia e/o chirurgia (compresa la radiochirurgia) e stabili da almeno 3 mesi prima dell'inizio del trattamento.
    9. Uso di anticoagulanti orali a dosi terapeutiche .
    10. Assenza negli ultimi 6 mesi di: infarto del miocardio; angina non controllata; innesto di bypass dell'arteria coronarica/periferica; insufficienza cardiaca congestizia sintomatica; evento cerebrovascolare; attacco ischemico transitorio.
    11. Trattamento cronico con corticosteroidi o altri agenti immunosoppressori . I soggetti con metastasi cerebrali che richiedono corticosteroidi sistemici non sono eleggibili.
    12. Pazienti con patologie non controllate, significative in corso o recenti
    13. Chirurgia maggiore (ad es. Chirurgia gastrointestinale, rimozione o biopsia delle metastasi cerebrali) entro 3 mesi prima dell'inizio del trattamento. La guarigione completa della ferita da un intervento chirurgico maggiore deve essere avvenuta 1 mese prima dell'inizio del trattamento e da un intervento chirurgico minore (ad es. Escissione semplice, estrazione del dente) almeno 10 giorni prima dell'inizio del trattamento. I soggetti con complicanze in corso clinicamente rilevanti derivanti da un precedente intervento chirurgico non sono eleggibili.
    14. Intervallo QT corretto, calcolato dalla formula di Fridericia, (QTcF)> 500 msec entro 1 mese prima dell'inizio del trattamento
    15. La vaccinazione entro 4 settimane dalla prima dose di avelumab e durante lo studio è vietata ad eccezione della somministrazione di vaccini inattivati.
    16. Malattia autoimmune attiva che potrebbe peggiorare quando si riceve un agente immuno-stimolante. Sono eleggibili i pazienti con diabete di tipo I, vitiligine, psoriasi o malattie ipo o ipertiroidee che non richiedono un trattamento immunosoppressivo.
    17. Uso corrente di farmaci immunosoppressori
    18. Storia di abuso di sostanze o condizioni mediche, psicologiche o sociali che possono interferire con la partecipazione del paziente allo studio o alla valutazione dei risultati dello studio.
    19. Malattie o condizioni mediche instabili che potrebbero compromettere la sicurezza del paziente e la sua compliance allo studio.
    20. Donne in gravidanza o in allattamento.
    21. Impossibilità di deglutire compresse o capsule.
    22. Ipersensibilità grave pregressa nota al prodotto in fase di sperimentazione o a qualsiasi componente nelle sue formulazioni, comprese le reazioni gravi di ipersensibilità note agli anticorpi monoclonali (grado NCI CTCAE = 3).
    E.5 End points
    E.5.1Primary end point(s)
    To evaluate the rate of patients free of progression at week 8 from axitinib discontinuation and avelumab maintenance after 36 weeks of induction treatment with the combination of avelumab and axitinib.
    Valutare, dopo 36 settimane di induzione con la combinazione di avelumab e axitinib, il rate di pazienti liberi da progressione all’ottava settimana dalla sospensione di axitinib e in mantenimento con avelumab.
    E.5.1.1Timepoint(s) of evaluation of this end point
    44 weeks
    44 settimane
    E.5.2Secondary end point(s)
    • Progression free survival in the overall population
    • Overall response rate in the overall population
    • Disease control rate in the overall population
    • Safety of the combination and of the avelumab alone after the combination.
    • To evaluate the Health-Related Quality Of Life (HRQOL) according to FKIS-19 questionnaire and Health status/utility (EQ-5D-5L) test.
    • To test the predictive role of the immunohistochemistry expression of PBRM1, PD-L1, CD31 and immune infiltration CD8+.
    • To evaluate the changes citokines evaluated at baseline, after 8 weeks of therapy and at tumor progression.
    • Sopravvivenza libera da progressione nella popolazione complessiva;
    • Tasso di risposta globale nella popolazione complessiva;
    • Tasso di controllo della malattia nella popolazione complessiva;
    • Profilo di sicurezza della combinazione dei due farmaci e del solo avelumab successivamente;
    • Valutare la qualità della vita correlata alla salute (HRQOL) secondo il questionario FKIS-19 e il questionario sullo stato di salute (EQ-5D-5L).
    • Testare il ruolo predittivo dell'espressione immunoistochimica di PBRM1, PD-L1, CD31 e dell’infiltrazione immunitaria CD8 +;
    • Valutare i cambiamenti delle citochine al baseline, a wk 8 e aprogressione di malattia
    E.5.2.1Timepoint(s) of evaluation of this end point
    - continuous -every 12 weeks during the treatment with avelumab plus axitinib. During the axitinib discontinuation every 8 weeks for the first six month and every 12 weeks thereafter
    - continuous -every 12 weeks during the treatment with avelumab plus axitinib. During the axitinib discontinuation every 8 weeks for the first six month and every 12 weeks thereafter
    - continuous -every 12 weeks during the treatment with avelumab plus axitinib. During the axitinib discontinuation every 8 weeks for the first six month and every 12 weeks thereafter
    - continuous - every 2 weeks
    - continuous - every 4 weeks
    - end of study
    - end of study
    - continuativo: ogni 12 settimane durante il trattamento combinato di Avelumab e axitinib. Successivamente durante il periodo di discontinuazione di axitinib ogni 8 settimane per i primi 6 mesi e poi ogni 12 settimane
    - continuativo: ogni 12 settimane durante il trattamento combinato di Avelumab e axitinib. Successivamente durante il periodo di discontinuazione di axitinib ogni 8 settimane per i primi 6 mesi e poi ogni 12 settimane
    - continuativo: ogni 12 settimane durante il trattamento combinato di Avelumab e axitinib. Successivamente durante il periodo di discontinuazione di axitinib ogni 8 settimane per i primi 6 mesi e poi ogni 12 settimane
    - continuativo: ogni 2 settimane
    - continuativo: ogni 4 settimane
    - analisi effettuate a fine studio
    - analisi effettuate a fine studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned21
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of trial will occur 30 days after the last patient last cycle
    30 giorni dopo l'ultimo ciclo dell'ultimo paziente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 60
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 15
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state75
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 75
    F.4.2.2In the whole clinical trial 75
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients who develop radiological disease progression on study treatment but are otherwise continuing to derive clinical benefit from study treatment will be eligible to continue with avelumab combined with axitinib, or single-agent avelumab, or single-agent axitinib provided that the treating physician has determined that the benefit/risk for doing so is favorable.
    I pazienti che sviluppano una progressione della malattia radiologica durante il trattamento in studio ma che continuano a trarre beneficio clinico dal trattamento in studio potranno continuare ad assumere avelumab in associazione con axitinib, o avelumab come singolo agente o axitinib come singolo agente a condizione che il medico curante abbia stabilito che il rapporto beneficio / rischio è favorevole per continuare l'assunzione
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-05-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-06-18
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-05-15
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:32:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA